Three Phase 3 Trials, Three Decisions to Measure Steroid-Toxicity Directly
Patients on long-term steroids for autoimmune and inflammatory diseases know the damage that these drugs cause. The question for sponsors has long been whether a trial can prove it. In June 2026, ...
Obexelimab Reduces Disease Flares and Steroid-Toxicity in IgG4-RD
An exciting Phase 3 trial has confirmed that obexelimab significantly reduces the risk of disease flare in IgG4-related disease (IgG4-RD) while also delivering measurable reductions in ...
Promising Monoclonal Antibody Offers New Steroid-Sparing Hope for IgG4-RD
Results from the Phase 3 MITIGATE trial of a biologic called inebilizumab have raised hopes the tide may be turning in the hunt for an alternative treatment to steroids for IgG4-related disease ...
New Insights on the Impact of IgG4-related Disease
Although ongoing research continues to advance our understanding of IgG4-related disease (IgG4-RD), the epidemiology and downstream consequences of this relatively rare and complex autoimmune ...
Obexelimab: A New Hope for IgG4-RD Treatment?
Exciting results from an open-label Phase 2 pilot trial published in Lancet Rheumatology[1] suggest that obexelimab, a potential new treatment for IgG4-related disease (IgG4-RD), may become an ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
